Market News & Trends
Recce Pharmaceuticals Announces Positive Safety Data From Third Cohort of Phase 1 Clinical Trial
Recce Pharmaceuticals Ltd recently reported Phase 1 intravenous (IV) clinical trial of RECCE 327 (R327) cohort three at 500mg (tenfold increase on cohort one 50mg…
Valneva & Pfizer Report Further Positive Phase 2 Data for Lyme Disease Vaccine Candidate
Valneva SE and Pfizer Inc. recently reported further positive Phase 2 data for their Lyme disease vaccine candidate, VLA15. Based on these new results….
Kintara Therapeutics Announces Issuance of New US Patent Related to VAL-083 & MGMT Resistance: Implications for Targeting Brain Tumor Stem Cells
Kintara Therapeutics, Inc. recently announced the US PTO has issued to Kintara United States Patent No. 11,234,955 covering a method of treating brain tumors including…
Adamis Pharmaceuticals Provides Enrollment Update of Subjects in Phase 2/3 Study of Tempol for the Treatment of COVID-19
Adamis Pharmaceuticals Corporation recently announced the enrollment and dosing of more than 100 subjects in the Company’s ongoing Phase 2/3 study of Tempol for the treatment of….
POP Biotechnologies Vaccine Technology to Enter Phase 3 Clinical Studies as Part of Eubiologics' COVID-19 Vaccine Candidate, EuCorVac-19
POP Biotechnologies recently announced the approval of the plan for a Phase 3 clinical study of EuCorVac-19, a COVID-19 vaccine candidate developed by South Korean…
Evelo Biosciences Announces Highly Significant Reductions in Clinically Validated Inflammatory Cytokines in EDP1815 Phase 2 Psoriasis Trial
Evelo Biosciences, Inc. recently announced the results of immunological biomarker analyses from its previously reported Phase 2 trial of orally-dosed EDP1815 in mild and moderate…
Theralase Demonstrates Proof-of-Concept for Canadian-Made COVID-19 Vaccine
Theralase Technologies Inc. has demonstrated proof-of-concept for the development of a Canadian-made SARS-CoV-2 (COVID-19) vaccine…..
uniQure Announces Dosing of First Patients in European Open-Label Clinical Trial of AMT-130 Gene Therapy in Huntington’s Disease
uniQure N.V. recently announced the dosing of the first two patients in its European open-label Phase 1b/2 clinical trial of AMT-130, a potential one-time gene-therapy…
NGM Bio’s NGM621 Receives Fast-Track Designation for the Treatment of Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration
NGM Biopharmaceuticals, Inc. recently announced the US FDA has granted Fast-Track designation to NGM621, a monoclonal antibody product candidate engineered to potently inhibit complement C3, for the treatment of….
Entasis Therapeutics Receives Acquisition Proposal From Existing Majority Stockholder Innoviva Inc.
Entasis Therapeutics Holdings Inc. recently announced its Board of Directors received a preliminary, non-binding proposal from its majority stockholder Innoviva, Inc. to acquire all….
Immunic Receives Notice of Allowance for Composition-of-Matter Patents in the US & Europe for IMU-935, a Potentially Best-in-Class Oral IL-17 Inhibitor
Immunic, Inc. recently announced the company received a Notice of Allowance from the USPTO for patent application 16/644581 titled IL-17 and IFN-gamma inhibition for the…
ImCheck Announces First Patients Dosed in Phase 2 of EVICTION Trial for ICT01
ImCheck Therapeutics recently announced the first patients have been dosed in the Phase 2a monotherapy expansion arm in the ongoing Phase 1/2a EVICTION clinical trial…
Pardes Biosciences Announces FDA Clearance of IND Application for Oral Antiviral Drug Candidate for the Treatment & Prevention of SARS-CoV-2 Infections
Pardes Biosciences, Inc. recently announced its Investigational New Drug (IND) application for PBI-0451 has been cleared by the US FDA. “As we enter our third…
Arch Scientists Publish Data on the Mechanism of Action & Efficacy of Lead Drug Candidate LSALT Peptide in the Prevention of Acute Kidney Injury
Arch Biopartners Inc. recently announced a scientific team led by Dr. Daniel Muruve at the University of Calgary, and their collaborators, have published a paper…
Pharmazz Inc. Submits INDA to India Central Drugs Standard Control Organization for Phase 2 Clinical Trial of Sovateltide in Hypoxic-Ischemic Encephalopathy in Neonates
Pharmazz, Inc. recently announced it has submitted an Investigational New Drug Application (INDA) to the India Central Drugs Standard Control Organization (CDSCO) for a Phase…
Regio Biosciences Enters License Agreement With AstraZeneca for Phase 2a Asset in Peripheral Artery Disease
Regio Biosciences, a Hibiscus BioVentures company, recently announced it has entered into an exclusive license agreement with AstraZeneca to further develop REG-101, a novel therapeutic…
Silo Pharma Extends Exclusive Option Agreement for Homing Peptides
Silo Pharma, Inc. recently announced it has extended its exclusive option agreement with the University of Maryland, Baltimore, to explore a novel invention generally known as….
CordenPharma Completes Acquisition of Three Manufacturing Facilities From Vifor Pharma
CordenPharma recently announced the completion of the acquisition of three manufacturing facilities from Vifor Pharma, to be ultimately renamed Corden Pharma Fribourg S.A. (including its…
Nashville Biosciences Collaborates With Datavant to Accelerate Life Sciences Drug Discovery & Clinical Research
Nashville Biosciences and Datavant recently announced a collaboration that will enable biopharma companies to connect their trial data to research datasets from BioVU. The linkages…
Tarsus Completes Enrollment for the Pivotal Phase 3 Saturn-2 Trial of TP-03 to Treat Demodex Blepharitis & Secures $175 Million Credit Facility
Tarsus Pharmaceuticals, Inc. recently announced it has completed enrollment of Saturn-2, the company’s second pivotal Phase 3 trial of TP-03 (lotilaner ophthalmic solution, 0.25%) for patients with….
